Privia Health Group (PRVA) AI Stock Analysis

• Market Cap: $2.72B
• Dividend Yield: N/A
• Average Volume (3M): 843.62K
• Price to Earnings (P/E): 126.4
• Beta (1Y): 0.68
• Revenue Growth: 19.01%
• EPS Growth: 38.68%
• Country: US
• Employees: 1,140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.07
• Shares Outstanding: 123,688,286
• 10 Day Avg. Volume: 875,371
• 30 Day Avg. Volume: 843,617
• PEG Ratio: 2.17
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 1.36
• P/FCF Ratio: 17.86
• Enterprise Value/Market Cap: -172.09
• Enterprise Value/Revenue: -220.19
• Enterprise Value/Gross Profit: -2.32K
• Enterprise Value/Ebitda: -9.18K
• 1Y Price Target: $32.09
• Price Target Upside: 46.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 0.36
• Revenue Forecast (FY): $2.38B

• Rating: 70 Outperform
• Price Target: $27.00 ▲(22.95% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

PRVA scores well on financial stability and cash generation, and the earnings call/guidance signals continued strong operating momentum into 2026. The score is held back primarily by a very expensive valuation (high P/E) and only mixed technical momentum (negative MACD despite price above moving averages).

Positive Factors

Consistent free cash flow generation

Privia’s persistent positive free cash flow across profitable and loss years demonstrates durable cash conversion and working-capital discipline. This stability funds operations, M&A and technology investment without reliance on external financing, supporting strategic flexibility even as tax status normalizes.

Rapid scale in providers and attributed lives

Meaningful and sustained growth in implemented providers and attributed lives boosts recurring service fees and shared-savings opportunity. Greater scale enhances negotiating leverage with payers, spreads fixed platform costs, and reinforces pathway to higher margin contribution as value-based programs mature.

Conservative balance sheet and low leverage

Very low debt and a growing equity base reduce refinancing and solvency risk, enabling Privia to invest in organic growth, M&A and technology without pressuring liquidity. This financial conservatism supports resilience to payer headwinds and provides runway for strategic initiatives.

Negative Factors

Structurally thin net profit margins

Persistently low net margins limit the company’s ability to absorb reimbursement pressure or higher operating costs and constrain retained earnings for reinvestment. Even with revenue growth, thin margins mean small adverse shifts in payer economics could materially reduce bottom-line results and ROE.

Payer and regulatory program uncertainty

Privia’s value-based revenue depends on payer program design and MA/Medicare policies. Structural changes or contracting pressure can alter shared-savings pools and reimbursement economics, creating multi-quarter revenue and margin uncertainty that’s difficult to hedge and affects predictability of incentive income.

Integration and platform conversion risk for acquired ACOs

The recent ACO acquisition adds lives but requires platform migration to realize savings and margin uplift. Execution delays or slower-than-expected conversions can postpone expected cash flow and synergy benefits, creating medium-term execution risk and tempering near-term accretion from M&A.

Privia Health Group Business Overview & Revenue Model

Company Description

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.

How the Company Makes Money

Privia Health generates revenue through a multi-faceted model that primarily includes service fees from healthcare providers who utilize its technology and management services. Key revenue streams consist of subscription fees for its platform, performance-based incentives tied to value-based care initiatives, and fees for ancillary services such as care coordination and patient engagement tools. Strategic partnerships with payers and healthcare organizations further bolster its earnings by facilitating broader access to its services and enhancing its value proposition in the healthcare market.

Privia Health Group Financial Statement Overview

Summary

Financials reflect a stable profile: very low leverage and a growing equity base, consistently positive free cash flow (even during loss years), and improved profitability versus 2021–2022. The main limiter is structurally thin net margins in 2023–2024, and the 2025 revenue figure is noted as an outlier that warrants caution.

Income Statement

Revenue growth is strong across the historical annual periods (notably 2022 and 2023), and the company has returned to profitability after losses in 2021–2022. However, profitability remains thin: recent net profit margins are around ~0.8%–1.4% (2023–2024), well below the stronger 2020 level, which suggests limited pricing power and/or elevated operating costs. The 2025 annual revenue figure appears abnormally large versus prior years, so margin-based improvements in that period should be interpreted cautiously.

Balance Sheet

The balance sheet looks conservatively financed with very low leverage in recent years (debt is ~1% of equity in 2023–2024), which reduces refinancing and solvency risk. Equity has grown over time, supporting a stronger capital base. Returns on equity have improved from negative levels in 2021–2022 to modestly positive in 2023–2024, but they are still not high, reflecting the business’s relatively low profitability.

Cash Flow

Cash generation is a clear positive: free cash flow is consistently positive across all years shown, including during loss-making periods, indicating good cash conversion and working-capital discipline. Free cash flow broadly tracks net income closely (roughly near 1x in most years), supporting earnings quality. That said, cash flow relative to the company’s operating earnings base is not especially high (coverage ratios in the ~0.18–0.29 range), which suggests cash generation is solid but not exceptionally strong versus reported operating performance.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.12B	1.74B	1.66B	1.36B	966.22M
Gross Profit	199.52M	176.85M	161.50M	134.78M	63.66M
EBITDA	53.84M	24.25M	27.18M	-14.55M	-214.97M
Net Income	22.92M	14.38M	23.08M	-8.59M	-188.23M
Balance Sheet
Total Assets	1.37T	1.14B	999.90M	792.81M	686.37M
Cash, Cash Equivalents and Short-Term Investments	479.69B	491.15M	389.51M	347.99M	320.58M
Total Debt	9.53B	5.59M	8.29M	11.50M	46.50M
Total Liabilities	578.43B	452.34M	392.51M	273.76M	236.19M
Stockholders Equity	737.22B	635.18M	561.44M	499.09M	426.87M
Cash Flow
Free Cash Flow	162.20M	104.26M	80.67M	47.09M	54.51M
Operating Cash Flow	163.40M	109.28M	80.78M	47.20M	55.06M
Investing Cash Flow	-181.57M	-10.32M	-48.01M	-104.00K	-32.77M
Financing Cash Flow	6.70M	2.68M	8.74M	-19.68M	213.66M

Privia Health Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRVA, the sentiment is Negative. The current price of 21.96 is below the 20-day moving average (MA) of 22.73, below the 50-day MA of 22.89, and below the 200-day MA of 22.88, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 43.58 is Neutral, neither overbought nor oversold. The STOCH value of 11.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRVA.

Privia Health Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRVA	70 Outperform	$2.72B	126.39	0.01%	―	19.01%	38.68%
HSTM	69 Neutral	$615.60M	37.76	5.87%	0.52%	3.68%	5.62%
TDOC	53 Neutral	$961.56M	-6.16	-14.24%	―	-2.37%	77.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DH	47 Neutral	$157.09M	-2.20	-47.69%	―	-5.30%	46.01%
EVH	46 Neutral	$337.15M	-0.27	-69.22%	―	-16.65%	-71.92%

Privia Health Group Corporate Events

Privia Health Finalizes Acquisition of ACO Business

Privia Health Group, Inc. announced the acquisition of an Accountable Care Organization business from Evolent Health, Inc. The transaction, which was initially announced on September 23, 2025, was finalized on December 5, 2025, potentially enhancing Privia’s market positioning and operational capabilities.

The most recent analyst rating on (PRVA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.